Artia Global Partners LP
13F Reported Value
ⓘ$541.9M
incl. option notional
Equity Holdings
ⓘ$526.0M
Option Notional
ⓘ$15.8M
$15.8M puts / $0 calls
Holdings
48
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Artia Global Partners LP disclosed 48 positions worth $541.9M in its Form 13F-HR for Q2 2026 — $526.0M in common stock plus $15.8M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ABVX (Abivax S.A.) at 13.1% of the equity portfolio, followed by $INSM and $TRVI. During the quarter the fund opened 7 new positions and exited 9 — including a new stake in $ALKS and a full exit from $INSM. The portfolio is most concentrated in Healthcare (97.9% of disclosed assets). All figures are sourced directly from Artia Global Partners LP’s Form 13F-HR filing with the SEC under CIK 1937964.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$68.8M516,447 sh - 39.4#2,150
Quality
$62.8M589,052 sh - —
Quality
$41.2M2,210,852 sh - 63.3
Quality
$36.1M517,315 sh - —
Quality
$34.7M185,390 sh - —
Quality
$27.6M29,739 sh - —
Quality
$23.5M448,964 sh - 56.6
Quality
$19.3M339,033 sh - —
Quality
$18.7M98,376 sh - —
Quality
$17.1M503,936 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Abivax S.A.$ABVX | — | $68.8M | 516,447 |
 INSMED Inc$INSM | 39.4#2,150 | $62.8M | 589,052 |
 Trevi Therapeutics, Inc.$TRVI | — | $41.2M | 2,210,852 |
 BrightSpring Health Services, Inc.$BTSG | 63.3 | $36.1M | 517,315 |
 Revolution Medicines, Inc.$RVMD | — | $34.7M | 185,390 |
 ARGENX SE$ARGX | — | $27.6M | 29,739 |
 Alkermes plc.$ALKS | — | $23.5M | 448,964 |
 Travere Therapeutics, Inc.$TVTX | 56.6 | $19.3M | 339,033 |
 ASTRAZENECA PLC$AZN | — | $18.7M | 98,376 |
 NewAmsterdam Pharma Co N.V.$NAMS | — | $17.1M | 503,936 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Artia Global Partners LP's 48 positions.
Showing top 10 of 48 holdings.
Sector Allocation
Healthcare
$515.1M
Technology
$11.0M
Full Holdings — Artia Global Partners LP (Q2 2026)
All 48 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ABVX | Abivax S.A. | $68.8M | 13.1% | -14% | — |
| 2 | $INSM | INSMED Inc | $62.8M | 11.9% | -6% | 39.4 |
| 3 | $TRVI | Trevi Therapeutics, Inc. | $41.2M | 7.8% | +10% | — |
| 4 | $BTSG | BrightSpring Health Services, Inc. | $36.1M | 6.9% | +862% | 63.3 |
| 5 | $RVMD | Revolution Medicines, Inc. | $34.7M | 6.6% | +48% | — |
| 6 | $ARGX | ARGENX SE | $27.6M | 5.3% | +0% | — |
| 7 | $ALKS | Alkermes plc. | $23.5M | 4.5% | NEW | — |
| 8 | $TVTX | Travere Therapeutics, Inc. | $19.3M | 3.7% | +380% | 56.6 |
| 9 | $AZN | ASTRAZENECA PLC | $18.7M | 3.5% | +3% | — |
| 10 | $NAMS | NewAmsterdam Pharma Co N.V. | $17.1M | 3.3% | +0% | — |
| 11 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $15.9M | 3.0% | +0% | 22.6 |
| 12 | — | SPDR SERIES TRUST - ST STR SP BIOT | $15.8M | — | NEW | — |
| 13 |  $DGX | QUEST DIAGNOSTICS INC | $13.8M | 2.6% | +60% | 69 |
| 14 |  $IONS | IONIS PHARMACEUTICALS INC | $11.4M | 2.2% | +0% | 23.4 |
| 15 |  $EYPT | EyePoint, Inc. | $11.0M | 2.1% | +0% | 3.5 |
| 16 |  $ALMS | ALUMIS INC. | $7.8M | 1.5% | -14% | 7.1 |
| 17 |  $VKTX | Viking Therapeutics, Inc. | $7.1M | 1.3% | +0% | — |
| 18 |  $CELC | Celcuity Inc. | $6.2M | 1.2% | +281% | — |
| 19 |  $CYTK | CYTOKINETICS INC | $6.0M | 1.1% | +334% | 28.1 |
| 20 |  $MRK | Merck & Co., Inc. | $6.0M | 1.1% | +0% | 59.9 |
| 21 |  $RAPP | Rapport Therapeutics, Inc. | $5.8M | 1.1% | +0% | — |
| 22 |  $JNJ | JOHNSON & JOHNSON | $5.7M | 1.1% | +0% | 69 |
| 23 |  $GH | Guardant Health, Inc. | $5.7M | 1.1% | NEW | 39 |
| 24 |  $ABSI | Absci Corp | $5.4M | 1.0% | NEW | 7 |
| 25 |  $SRRK | Scholar Rock Holding Corp | $5.3M | 1.0% | +0% | — |
| 26 |  $SION | Sionna Therapeutics, Inc. | $5.3M | 1.0% | +0% | — |
| 27 |  $ASND | Ascendis Pharma A/S | $4.7M | 0.9% | +0% | 44.8 |
| 28 |  $ROIV | Roivant Sciences Ltd. | $4.6M | 0.9% | +0% | — |
| 29 |  $PALI | PALISADE BIO, INC. | $4.2M | 0.8% | +0% | — |
| 30 |  $EWTX | Edgewise Therapeutics, Inc. | $4.0M | 0.8% | +51% | — |
| 31 |  $BIIB | BIOGEN INC. | $4.0M | 0.8% | +0% | 64.7 |
| 32 |  $XENE | Xenon Pharmaceuticals Inc. | $3.9M | 0.8% | +0% | 24 |
| 33 |  $BLTE | BELITE BIO, INC | $3.8M | 0.7% | +0% | — |
| 34 |  $MLYS | Mineralys Therapeutics, Inc. | $3.7M | 0.7% | +0% | — |
| 35 |  $PROK | PROKIDNEY CORP. | $3.7M | 0.7% | +0% | 25.8 |
| 36 |  $ELVN | Enliven Therapeutics, Inc. | $3.7M | 0.7% | +245% | — |
| 37 |  $ORKA | Oruka Therapeutics, Inc. | $3.2M | 0.6% | NEW | — |
| 38 |  $PTGX | Protagonist Therapeutics, Inc | $2.8M | 0.5% | +0% | 59.4 |
| 39 |  $UTHR | UNITED THERAPEUTICS Corp | $2.7M | 0.5% | +0% | 71.3 |
| 40 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $2.7M | 0.5% | +0% | — |
| 41 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $1.9M | 0.3% | +0% | — |
| 42 |  $CMPX | Compass Therapeutics, Inc. | $839,208 | 0.2% | NEW | 28.1 |
| 43 |  $PRAX | Praxis Precision Medicines, Inc. | $836,975 | 0.2% | +0% | — |
| 44 |  $KOD | Kodiak Sciences Inc. | $663,060 | 0.1% | +0% | — |
| 45 |  $TENX | TENAX THERAPEUTICS, INC. | $612,264 | 0.1% | +0% | — |
| 46 |  $NUVL | Nuvalent, Inc. | $605,150 | 0.1% | +0% | — |
| 47 |  $PEPG | PepGen Inc. | $369,583 | 0.1% | +0% | — |
| 48 |  $SYRE | Spyre Therapeutics, Inc. | $355,120 | 0.1% | NEW | — |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Artia Global Partners LP including:
Track Artia Global Partners LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Artia Global Partners LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Artia Global Partners LP
13F Pro is an AI hedge fund tracker and stock research platform. For Artia Global Partners LP (SEC CIK: 1937964), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Artia Global Partners LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.